<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Polatuzumab vedotin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Polatuzumab vedotin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Polatuzumab vedotin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="121711" href="/d/html/121711.html" rel="external">see "Polatuzumab vedotin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F53298967"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Polivy</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F55194833"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Polivy</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F53265232"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anti-CD79B;</li>
<li>
                        Antineoplastic Agent, Antibody Drug Conjugate;</li>
<li>
                        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F53291371"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Administer <i>Pneumocystis jiroveci </i>pneumonia and herpes virus prophylaxis throughout polatuzumab vedotin treatment. If not already premedicated, administer an antihistamine and antipyretic at least 30 to 60 minutes prior to polatuzumab vedotin infusion. Administer prophylactic granulocyte colony-stimulating factor (G-CSF) for polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP); consider prophylactic G-CSF for polatuzumab vedotin in combination with bendamustine and rituximab. Administer tumor lysis syndrome prophylaxis for patients at increased risk of tumor lysis syndrome as clinically necessary.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e1466c1f-9e72-4291-bf57-959af15ed812">Diffuse large B-cell lymphoma, previously untreated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diffuse large B-cell lymphoma, previously untreated: </b>Pola-R-CHP regimen: <b>IV: </b>1.8 mg/kg once every 21 days for 6 cycles (in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHP); following the completion of 6 cycles of pola-R-CHP, rituximab alone was continued for 2 additional cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34904799']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34904799'])">Ref</a></span>). Refer to protocol for further information.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="48925eaf-0a5b-4db7-8ad8-85a7a9637b97">Diffuse large B-cell lymphoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diffuse large B-cell lymphoma, relapsed or refractory: IV:</b> 1.8 mg/kg once every 21 days for 6 cycles (in combination with bendamustine and rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31693429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31693429'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose: </i>If a polatuzumab vedotin dose is missed, administer as soon as possible. Adjust cycle schedule in order to maintain a 21-day interval between doses.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F53291373"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl 30 to 89 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, no clinically significant pharmacokinetic differences were observed based on CrCl 30 to 89 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage renal disease (with or without dialysis): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F53291374"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (total bilirubin 1 to 1.5 times ULN or AST &gt; ULN): No initial dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe impairment (total bilirubin &gt;1.5 times ULN and any AST): Avoid polatuzumab vedotin use; exposure to monomethylauristatin E (MMAE) may be increased and may lead to an increased incidence of adverse events.</p></div>
<div class="block doo drugH1Div" id="F57506830"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>:</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full, weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F53291380"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Recommended Polatuzumab Vedotin Dosage Adjustment Levels</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><tfoot>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;">
<sup>a</sup> If further dose reduction needed, discontinue polatuzumab vedotin.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Usual (initial) dose</p></td>
<td align="center">
<p style="text-indent:0em;">1.8 mg/kg once every 21 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">First dose reduction level</p></td>
<td align="center">
<p style="text-indent:0em;">1.4 mg/kg once every 21 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Second dose reduction level</p></td>
<td align="center">
<p style="text-indent:0em;">1 mg/kg once every 21 days<sup>a</sup></p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Polatuzumab Vedotin Dosage Modifications for Adverse Reactions<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">Adverse reaction</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Severity</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Dosage modification for Polatuzumab vedotin with R-CHP</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Dosage modification for Polatuzumab vedotin with bendamustine and rituximab</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> R-CHP = rituximab, cyclophosphamide, doxorubicin, and prednisone; G-CSF = granulocyte colony-stimulating factor; PML = progressive multifocal leukoencephalopathy.</p></td></tr>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> If neutropenia or thrombocytopenia are due to lymphoma, dose delay or reduction may not be necessary.</p></td></tr>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>R-CHP should be continued if polatuzumab vedotin is withheld.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">Hematologic toxicity<sup>b</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neutropenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3 or 4 (on day 1 of any cycle)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold all treatment until ANC recovers to ≥1,000/mm<sup>3</sup>.</p>
<p style="text-indent:0em;text-align:left;">Consider therapeutic G-CSF if neutropenia occurs after prophylactic G-CSF.</p>
<p style="text-indent:0em;text-align:left;">If ANC recovers to ≥1,000/mm<sup>3 </sup>on or before day 7, resume all treatment without any dose reductions.</p>
<p style="text-indent:0em;text-align:left;">If ANC recovers to ≥1,000/mm<sup>3 </sup>after day 7, resume all treatment and administer prophylactic G-CSF in next cycle. If G-CSF was already administered, consider a polatuzumab vedotin dose reduction.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold all treatment until ANC recovers to &gt;1,000/mm<sup>3</sup>. If ANC recovers to &gt;1,000/mm<sup>3</sup> on or before day 7, resume all treatment without any additional dose reductions. Consider G-CSF prophylaxis for subsequent cycles (if not previously administered).</p>
<p style="text-indent:0em;text-align:left;">If ANC recovers to &gt;1,000/mm<sup>3</sup> after day 7, resume all treatment; consider G-CSF prophylaxis for subsequent cycles (if not previously administered). If G-CSF prophylaxis was administered, consider dose reduction of bendamustine. If bendamustine dose has already been reduced, consider dose reduction of polatuzumab vedotin to 1.4 mg/kg.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Thrombocytopenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3 or 4 (on day 1 of any cycle)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold all treatment until platelets recover to ≥75,000/mm<sup>3</sup>.</p>
<p style="text-indent:0em;text-align:left;">If platelets recover to ≥75,000/mm<sup>3 </sup>on or before day 7, resume all treatment without any dose reductions.</p>
<p style="text-indent:0em;text-align:left;">If platelets recover to ≥75,000/mm<sup>3 </sup>after day 7, resume all treatment and consider a polatuzumab vedotin dose reduction.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold all treatment until platelets recover to &gt;75,000/mm<sup>3</sup>. If platelets recover to &gt;75,000/mm<sup>3</sup> on or before day 7, resume all treatment without any additional dose reductions.</p>
<p style="text-indent:0em;text-align:left;">If platelets recover to &gt;75,000/mm<sup>3</sup> after day 7, resume all treatment (with bendamustine dose reduction). If bendamustine dose has already been reduced, consider dose reduction of polatuzumab vedotin to 1.4 mg/kg.</p></td></tr>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">Nonhematologic toxicity</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Infusion reaction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grades 1 to 3</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">Interrupt polatuzumab vedotin infusion and administer supportive treatment.</p>
<p style="text-indent:0em;text-align:left;">Permanently discontinue polatuzumab vedotin for the first instance of grade 3 wheezing, bronchospasm, or generalized urticaria, or for recurrent grade 2 wheezing or urticaria, or recurrence of any grade 3 symptoms.</p>
<p style="text-indent:0em;text-align:left;">Otherwise, when symptoms completely resolve, resume polatuzumab vedotin infusion at 50% of the rate prior to the interruption. In the absence of infusion-related symptoms, the infusion rate may be escalated in increments of 50 mg/hour every 30 minutes.</p>
<p style="text-indent:0em;text-align:left;">For the next cycle, infuse polatuzumab vedotin over 90 minutes. If no infusion-related reaction occurs, subsequent infusions may be administered over 30 minutes. Administer premedications for all cycles.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">Stop polatuzumab vedotin infusion immediately and administer supportive treatment. Discontinue polatuzumab vedotin.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Peripheral neuropathy (type unspecified)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grades 2 to 3</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">See peripheral sensory neuropathy and peripheral motor neuropathy below.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold polatuzumab vedotin until improvement to ≤ grade 1. If recovery to ≤ grade 1 occurs on or before day 14, resume polatuzumab vedotin (with the next cycle) at a permanently reduced dose of 1.4 mg/kg. If grade 2 or 3 peripheral neuropathy occurs after the dose has already been reduced to 1.4 mg/kg, discontinue polatuzumab vedotin. If not recovered to ≤ grade 1 on or before day 14, discontinue polatuzumab vedotin.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Discontinue polatuzumab vedotin.</p></td></tr>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;text-align:left;">Peripheral sensory neuropathy<sup>c</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 1</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">No polatuzumab vedotin dosage modification necessary.</p></td>
<td align="center" rowspan="8">
<p style="text-indent:0em;text-align:left;">See peripheral neuropathy (type unspecified) above.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">If resolves to ≤ grade 1 before the next scheduled polatuzumab vedotin dose, resume at the same dose level. If grade 2 persists at the next scheduled dose, reduce polatuzumab vedotin one dose level.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold until ≤ grade 2 and reduce polatuzumab vedotin one dose level.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Permanently discontinue polatuzumab vedotin.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Peripheral motor neuropathy<sup>c</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 1</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">No polatuzumab vedotin dosage modification necessary.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 2 or 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold until ≤ grade 1 and reduce polatuzumab vedotin one dose level.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Permanently discontinue polatuzumab vedotin.</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">Peripheral neuropathy, concurrent sensory and motor<sup>c</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">If there is concurrent sensory and motor neuropathy, follow the modification recommendations for the most severe neuropathy. If the grade of sensory and motor neuropathy are the same, follow the modification recommendations for motor neuropathy.</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">Progressive multifocal leukoencephalopathy</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">Withhold treatment (polatuzumab and concomitant chemotherapy) with new-onset symptoms suggestive of PML; permanently discontinue if PML diagnosis confirmed.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F53291372"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F53427643"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Percentages reported as part of combination chemotherapy regimens in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (24%), skin rash (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoalbuminemia (13%), hypocalcemia (11%), hypokalemia (16%), increased uric acid (19%), weight loss (13% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (16%), constipation (29%), decreased appetite (17% to 27%), diarrhea (31% to 38%; grades ≥3: 4%), dysgeusia (14%), increased serum amylase (24%), increased serum lipase (7% to 36%), nausea (42%; grades 3/4: 1%), stomatitis (22%; grades 3/4: 1%), vomiting (15% to 18%; grades ≥3: 1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (47% to 68%; grades ≥3: 14% to 24%), febrile neutropenia (15%; grades ≥3: 4% to 15%), lymphocytopenia (13% to 80%, grades ≥3: 9% to 44%), neutropenia (49% to 60%; grades ≥3: 13% to 42%), thrombocytopenia (32% to 49%; grades ≥3: 8% to 40%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (25% to 38%), increased serum alkaline phosphatase (23%), increased serum aspartate transaminase (26% to 36%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction (13% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (including cytomegalovirus disease, herpes virus infection, and sepsis [≤7%]; grades 3/4: 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (13%), fatigue (37%), headache (13%), peripheral neuropathy (40% to 53%; grades 3/4: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (66% to 87%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (15%), dyspnea (13%), pneumonia (22%; including pneumonia due to <i>Pneumocystis jirovecii</i> and fungal pneumonia), upper respiratory tract infection (13% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (16% to 33%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypophosphatemia (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Pancytopenia (7%), tumor lysis syndrome (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (1% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal insufficiency (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonitis (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hepatic: Hepatotoxicity, increased serum bilirubin</p></div>
<div class="block coi drugH1Div" id="F53265235"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to polatuzumab vedotin or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F53291341"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Serious or severe myelosuppression may occur with polatuzumab vedotin treatment. Grade 3 or higher neutropenia, thrombocytopenia, anemia, lymphopenia, and neutropenic fever have been reported. Most patients who received polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone received primary prophylaxis with granulocyte colony-stimulating factor (G-CSF); almost half of patients who received polatuzumab vedotin with bendamustine and rituximab received primary prophylaxis with G-CSF.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Serious hepatotoxicity has occurred; cases were consistent with hepatocellular injury, with elevations of transaminases and/or bilirubin. Grade 3 and 4 transaminase elevations occurred in a small percentage of patients. The risk for hepatotoxicity may be increased with preexisting liver disease, elevated baseline liver enzymes, and concurrent hepatotoxic medications.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Serious and/or fatal infection, including opportunistic infections such as sepsis, pneumonia (including <i>Pneumocystis jirovecii</i> and other fungal pneumonia), herpesvirus, and cytomegalovirus have occurred. Prophylaxis for <i>P. jirovecii </i>pneumonia and herpes virus is required throughout polatuzumab vedotin treatment. Grade 3 or higher infection has occurred; infection-related mortality was reported in a small percentage of patients within 90 days of the last treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion-related reactions: Infusion-related reactions, including severe cases, have been reported. Symptoms included fever, chills, dyspnea, pruritus, rash, and chest discomfort; most reactions were grade 1 or 2 in nature. Infusion reactions may occur as late as 24 hours after administration. Premedicate prior to polatuzumab vedotin administration with an antihistamine and antipyretic.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral neuropathy: Polatuzumab vedotin may cause peripheral neuropathy, which may be severe and/or cumulative; may worsen preexisting peripheral neuropathy. Neuropathy may occur as early as the first cycle of therapy. Neuropathy is usually sensory, although motor and sensorimotor peripheral neuropathy has also been observed; the majority of cases were grade 1 or 2 (grade 3 toxicity has also been reported). The median time to onset was 2.1 to 2.3 months; neuropathy completely resolved in approximately one-half of patients, and a majority of patients saw improvement or resolution of neuropathy after a median of 1 or 4 months.</p>
<p style="text-indent:-2em;margin-left:4em;">• Progressive multifocal leukoencephalopathy: Progressive multifocal leukoencephalopathy (PML) has been reported with polatuzumab vedotin when used in combination with bendamustine and rituximab.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: Tumor lysis syndrome (TLS) may occur; risk of TLS is higher in patients with a high tumor burden and/or with rapid tumor proliferation.</p></div>
<div class="block foc drugH1Div" id="F53298968"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Polivy: Polatuzumab vedotin-piiq 30 mg (1 ea); Polatuzumab vedotin-piiq 140 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F53298966"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F53305094"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Polivy Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $4,511.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">140 mg (per each): $21,051.65</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F55194834"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Polivy: 30 mg (1 ea); 140 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F53291383"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse the initial dose over 90 minutes. Infuse using a dedicated infusion line with a sterile, nonpyrogenic, low-protein binding in-line or add-on 0.2- or 0.22-micron filter. Monitor for infusion-related reactions during infusion and for a minimum of 90 minutes after the initial infusion is completed. If the initial infusion rate is well tolerated, subsequent doses may be infused over 30 minutes (monitor during infusion and for a minimum of 30 minutes after completion of infusion). Do not administer as IV push or bolus; do not mix or infuse with other medications.</p>
<p style="text-indent:-2em;margin-left:4em;">If not already premedicated, administer an antihistamine and antipyretic at least 30 to 60 minutes prior to each infusion. If an infusion-related reaction occurs, interrupt polatuzumab vedotin infusion and administer supportive treatment as necessary. See "Dosing: Adjustment for Toxicity" for infusion reaction management.</p>
<p style="text-indent:-2em;margin-left:4em;">For previously untreated diffuse large B-cell lymphoma, polatuzumab vedotin, cyclophosphamide, doxorubicin, and rituximab may be administered in any order on day 1 of each cycle after administration of the day 1 prednisone dose.</p>
<p style="text-indent:-2em;margin-left:4em;">For relapsed or refractory diffuse large B-cell lymphoma, polatuzumab vedotin, bendamustine, and rituximab may be administered in any order (on day 1 of each cycle).</p></div>
<div class="block hazard drugH1Div" id="F53291351"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;display:inline">Hazardous agent (NIOSH [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F53265234"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Diffuse large B-cell lymphoma, previously untreated: </b>Treatment (in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone; R-CHP) of previously untreated diffuse large B-cell lymphoma, in adults with not otherwise specified or high-grade B-cell lymphoma and with an International Prognostic Index score of 2 or greater.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Diffuse large B-cell lymphoma, relapsed or refractory:</b> Treatment of relapsed or refractory diffuse large B-cell lymphoma (in combination with bendamustine and a rituximab product) not otherwise specified, in adults, after at least two prior therapies.</p></div>
<div class="block mst drugH1Div" id="F53291281"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Polatuzumab vedotin may be confused with brentuximab vedotin, enfortumab vedotin, panitumumab, pembrolizumab, pertuzumab, rituximab, tisotumab vedotin</p>
<p style="text-indent:-2em;margin-left:4em;">Polivy may be confused with Poteligeo</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F53305229"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F53305226"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Polatuzumab Vedotin. Exposure to unconjugated MMAE, the cytotoxic small molecule component of polatuzumab vedotin, may be decreased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Polatuzumab Vedotin. Exposure to unconjugated MMAE, the cytotoxic small molecule component of polatuzumab vedotin, may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53291339"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to use in patients who could become pregnant. Patients who could become pregnant should use effective contraception during treatment and for 3 months after the last polatuzumab vedotin dose. Patients with partners who could become pregnant should use effective contraception during treatment and for 5 months after the last polatuzumab vedotin dose.</p></div>
<div class="block pri drugH1Div" id="F53291338"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to polatuzumab vedotin may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F53291340"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if polatuzumab vedotin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 2 months after the last polatuzumab vedotin dose.</p></div>
<div class="block mop drugH1Div" id="F53291382"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;">CBC throughout treatment; LFTs (liver enzymes and bilirubin). Verify pregnancy status (in patients who could become pregnant) prior to treatment initiation. Monitor during infusion and for at least 90 minutes after the first infusion and for at least 30 minutes after subsequent infusions for signs/symptoms of infusion-related reactions. Monitor for signs of neuropathy (hypoesthesia, hyperesthesia, paresthesia, dysesthesia, burning sensation, or neuropathic pain or weakness, or gait disturbance), tumor lysis syndrome, signs/symptoms of progressive multifocal leukoencephalopathy (new or worsening neurologic, cognitive, or behavioral changes) and infection (bacterial, fungal, or viral).</p>
<p style="text-indent:0em;margin-top:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F53291359"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Polatuzumab vedotin is an antibody drug conjugate (ADC) directed at CD79b which consists of 3 components: 1) a CD79b-specific humanized IgG1 antibody; 2) a microtubule-disrupting agent, monomethylauristatin E (MMAE); and 3) a protease cleavable linker (which covalently conjugates MMAE to the polatuzumab antibody). The conjugate binds to CD79b (B-cell specific cell surface protein commonly expressed in mature B cell lymphomas [Tilly 2019]), and forms a complex which is internalized within the cell and releases MMAE. MMAE binds to the tubules and disrupts the cellular microtubule network, inducing cell cycle arrest (G2/M phase) and apoptosis.</p></div>
<div class="block phk drugH1Div" id="F53291360"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Antibody-conjugated MMAE: 3.15 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: MMAE: 71% to 77%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Catabolism to small peptides, amino acids, unconjugated MMAE, and unconjugated MMAE-related catabolites; MMAE is a CYP3A4 substrate.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Antibody-conjugated MMAE: ~12 days (at end of cycle 6); unconjugated MMAE: ~4 days (after first dose).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: Antibody-conjugated MMAE: ~0.9 L/day (at end of cycle 6).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56521891"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ropolivy</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Ropolivy</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Polatuzumab vedotin roche</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Polivy</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polatuzumab-vedotin-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polatuzumab-vedotin-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>National Institute for Occupational Safety and Health (NIOSH) notice. Centers for Disease Control and Prevention website. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 25, 2019. Accessed September 26, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Genentech.1">
<a name="Genentech.1"></a>Polivy (polatuzumab vedotin) [prescribing information]. South San Francisco, CA: Genentech Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Polivy.1">
<a name="Polivy.1"></a>Polivy (polatuzumab vedotin) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Polivy.1">
<a name="Polivy.1"></a>Polivy (polatuzumab vedotin) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31693429">
<a name="31693429"></a>Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. <i>J Clin Oncol</i>. 2020;38(2):155‐165. doi:10.1200/JCO.19.00172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polatuzumab-vedotin-drug-information/abstract-text/31693429/pubmed" id="31693429" target="_blank">31693429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31101489">
<a name="31101489"></a>Tilly H, Morschhauser F, Bartlett NL, et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomized, phase 1b-2 study.<i> Lancet Oncol. </i>2019;20(7):998‐1010. doi:10.1016/S1470-2045(19)30091-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polatuzumab-vedotin-drug-information/abstract-text/31101489/pubmed" id="31101489" target="_blank">31101489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34904799">
<a name="34904799"></a>Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. <i>N Engl J Med</i>. 2022;386(4):351-363. doi:10.1056/NEJMoa2115304<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polatuzumab-vedotin-drug-information/abstract-text/34904799/pubmed" id="34904799" target="_blank">34904799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed September 26, 2019.</div>
</li></ol></div><div id="topicVersionRevision">Topic 121575 Version 113.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
